Resources
Access clinical papers, presentations, and FAQs about DeepGAD™.
Clinical Papers
Prospective Reader Study (2024)
Blinded neuroradiologist assessment of DeepGAD™ vs full-dose images in 101 cases.
Technical White Paper
Detailed methodology: AI architecture, training, and validation.
Presentations
RSNA 2023 Presentation
Scientific session recording and slides (35 min).
Investor Deck
Business overview, clinical validation, and roadmap.
Frequently Asked Questions
Is DeepGAD™ FDA-cleared?
DeepGAD™ is currently under clinical evaluation for FDA submission as a SaMD (Software as a Medical Device). It is available for investigational use in approved pilot sites.
What MRI scanners are supported?
DeepGAD™ works with all major 1.5T and 3T MRI systems. Our preprocessing normalizes inputs across scanner makes and models.
How does reimbursement work?
While contrast volume reduction doesn't currently have separate reimbursement, it contributes to cost savings for providers and may qualify for alternative payment models.